Skip to content

Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression

Brianna R. Altman, Mitch Earleywine, Joseph A. de Leo

Journal of Psychoactive Drugs January 3, 2022 DOI: 10.1080/02791072.2021.2020382 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Cross-sectional survey Peer reviewed
Sample size 803
Population Adults reporting depressive symptoms recruited from Amazon's MTurk platform
Interventions Cognitive-behavioral therapy Psilocybin-assisted therapy
Topics Psilocybin Depression
Keywords Credibility Psychological intervention Clinical psychology Depression economics Cognitive behavioral therapy Cognitive therapy Psychotherapist Cognition Hallucinogen
Citations 4
Key findings Individuals rated CBT as more credible than PAT, and those with therapy experience rated CBT higher than those without.

Abstract

Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin has generated media attention and empirical support for antidepressant effects, but lay impressions of its effectiveness are unclear. Although perceptions of treatment credibility contribute to outcome, beliefs about the credibility of psilocybin-assisted therapy (PAT) among potential patients remain uninvestigated, especially relative to cognitive-behavioral therapy (CBT), a common, empirically-validated approach. The present study examined credibility ratings for CBT and PAT among individuals reporting depressive symptoms. Participants (N = 803) from Amazon's MTurk platform reported demographics, depressive symptoms, and psychotherapy experience, then read data-based vignettes describing each therapy and rated their credibility. Individuals rated CBT as more credible than PAT. Those with therapy experience rated CBT as more credible than those without. Men and lifetime hallucinogen users rated PAT more credible than women and non-users, but few other predictors accounted for much variance in credibility. Results suggest that potential clients appear cautious about PAT. As continued work examines the effectiveness of psychedelic-assisted interventions, researchers and clinicians must consider patients' beliefs about treatments as potential predictors of outcomes. Additionally, the paradigm used here might have potential for examining credibility of many interventions.

Comparable studies

Other cross-sectional and survey studies on psilocybin for depression, most cited first.

Study Year Design Participants
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers Self-selected microdosers and non-microdosers recruited via a mobile application 2021 Cross-sectional survey n = 8,703
Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. Adults with at least one lifetime psychedelic experience 2022 Cross-sectional survey n = 2,510
How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? MTurk respondents with depressive symptoms 2022 Cross-sectional survey n = 800
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Australians, including individuals with and without self-identified mental illness 2024 Cross-sectional survey n = 502
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Healthcare providers who treat psychiatric disorders with medications and have at least... 2023 Secondary analysis of a cross-sectional online survey n = 228

Explore topics

By condition and practice